FDA wary of drugs developed in China

(By Erica Carbajal for Becker’s Hospital Review)

The FDA is concerned about the quality of studies evaluating cancer drugs and other new medicines developed in China, The Wall Street Journal reported Feb. 9. Continue reading here…

Notice: The link provided above connects readers to the full content of the posted article. The URL (internet address) for this link is valid on the posted date; medicarereport.org cannot guarantee the duration of the link’s validity. Also, the opinions expressed in these postings are the viewpoints of the original source and are not explicitly endorsed by AMAC, Inc.; the AMAC Foundation, Inc.; or medicarereport.org